|Board Committees | Management | Board of Directors|
China Biologic Products, Inc. (Nasdaq: CBPO), is one of the largest non-state-owned fully integrated plasma-based biopharmaceutical companies in China. Our products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. Our core capabilities include plasma collection, research and development, production, and commercialization of biopharmaceutical products.
Currently we produce more than 20 plasma-based products and have a pipeline of new and developing products to drive our future in China’s growing plasma market. To complement our organic growth, we consider acquisitions to expand our plasma collection capabilities in China. We are constantly at work to enhance our R&D and technological capabilities to create new products and to improve our existing products and processes.
We sell directly to hospitals and other healthcare facilities in China and are reducing the use of independent distributors.
Our headquarters is in the city of Beijing. We manufacture in our indirect majority-owned subsidiaries, Shandong Taibang Biological Products and Guiyang Dalin Biologic Technologies, and have an equity investment in Xi’an Huitian Blood Products.
|Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.|
|Audit Committee||Compensation Committee||Corp. Gov. & Nom. Committee|
|David (Xiaoying) Gao|
|Dr. Yungang Lu|
|Charles (Le) Zhang|
|Albert (Wai Keung) Yeung|
|Prof. Wenfang Liu|
|Dr. Bing Li|